中文 
English 
| 产品编号 | RC30011 |
| 中文名称 | 曲妥珠单抗 |
| 英文名称 | Trastuzumab (anti-HER2) |
| CAS编号 | 180288-69-1 |
| 分子量 | 145.53 KD |
| 靶点 | HER2 |
| 配制 | 1×PBS, pH6.0 |
| 推荐同型对照 | Human IgG1 |
| 来源 | CHO cells |
| 除菌 | 0.2 μM filtered |
| 储存条件 | Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles |
| 描述 | Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer. Targets(IC50) EGFR,ADC Antibody |
| In vitro | METHODS: Human breast cancer cells BT-474 were treated with Trastuzumab (0.01-10 μg/mL) for 72 h. Cell viability was determined by MTS Assay. RESULTS: The antiproliferative effect of Trastuzumab was observed at concentrations as low as 0.5 μg/mL, with a stabilizing level of approximately 10 μg/mL. METHODS: CHO-K6, CHO-EGFR and CHO-HER3 cells were treated with Trastuzumab (0.1-10 μg/mL) for 5-60 min, and binding to HER receptors was detected by Immunofluorescence. RESULTS: Trastuzumab binds only to HER2, but not to EGFR and HER3. |
| In vivo | METHODS：To test the in vivo antitumor activity, Trastuzumab (5 μg/g) was administered intraperitoneally once a week for seven doses to nude mice harboring human mammary carcinoma tumor JIMT-1. RESULTS: Trastuzumab had a significant inhibitory effect on tumor growth on days 21- 56. After stopping administration, tumors began to grow in two nude mice whose tumors were palpable earlier. |
